Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PAK4 | O96013 | 2/20 | 0.46 |
| ▸ | NAMPT | P43490 | 1/20 | 0.39 |
| ▸ | PAK1 | Q13153 | 1/20 | 0.39 |
| ▸ | GABRA5 | P31644 | 1/20 | 0.39 |
| ▸ | HRH3 | Q9Y5N1 | 6/20 | 0.39 |
| ▸ | HTR1A | P08908 | 6/20 | 0.37 |
| ▸ | PRKAA2 | P54646 | 2/20 | 0.36 |
| ▸ | DRD2 | P14416 | 1/20 | 0.36 |
| ▸ | DRD4 | P21917 | 1/20 | 0.36 |
| ▸ | DRD3 | P35462 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18542112 | 0.89 | PAK4 (0.44) | PAK4NAMPTPAK1GABRA5HRH3 | |
| SCHEMBL18530603 | 0.89 | PAK4 (0.45) | PAK4NAMPTPAK1GABRA5HRH3 | |
| SCHEMBL18530579 | 0.88 | PAK4 (0.44) | PAK4NAMPTPAK1GABRA5HRH3 | |
| SCHEMBL18530616 | 0.85 | PAK4 (0.67) | PAK4NAMPTPAK1GABRA5HRH3 | |
| SCHEMBL18530617 | 0.85 | PAK4 (0.67) | PAK4NAMPTPAK1GABRA5HRH3 | |
| SCHEMBL16345167 | 0.82 | PAK4 (0.57) | PAK4NAMPTPAK1GABRA5HRH3 | |
| SCHEMBL18530652 | 0.82 | PAK4 (0.38) | PAK4GABRA5HRH3HTR1A | |
| SCHEMBL21143171 | 0.81 | PAK4 (0.38) | PAK4HRH3 | |
| SCHEMBL18542145 | 0.80 | PAK4 (0.43) | PAK4NAMPTPAK1GABRA5HRH3 | |
| SCHEMBL18530545 | 0.79 | HTR1A (0.35) | PAK4NAMPTPAK1HTR1A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20190218207-A1 | 3-(Pyridin-3-yl)-Acrylamide and N-(Pyridin-3-yl)-Acrylamide Derivatives and Their Use as PAK or NAMPT Modulators | Karyopharm Therapeutics Inc. | 2019-07-18 | — | — | US | disclosed |
| EP-3337796-A1 | 3-(PYRIDIN-3-YL)-ACRYLAMIDE AND N-(PYRIDIN-3-YL)-ACRYLAMIDE DERIVATIVES AND THEIR USE AS PAK OR NAMPT MODULATORS | Karyopharm Therapeutics, Inc. (US) | 2018-06-27 | — | — | EP | disclosed |
| WO-2017031213-A1 | 3-(PYRIDIN-3-YL)-ACRYLAMIDE AND N-(PYRIDIN-3-YL)-ACRYLAMIDE DERIVATIVES AND THEIR USE AS PAK OR NAMPT MODULATORS | Karyopharm Therapeutics Inc. (US) | 2017-02-23 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190218207-A1 | 3-(Pyridin-3-yl)-Acrylamide and N-(Pyridin-3-yl)-Acrylamide Derivatives and Their Use as PAK or NAMPT Modulators | NAMPT, PAK3, PAK5 | PAK4 7/4885NAMPT 1/4885PAK1 5/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.